AR226356A1 - Procedimiento para preparar derivados de 2-metil-3-(2-hidroxi-3-amino-propoxi)-4,5-di-oximetil-piridina - Google Patents

Procedimiento para preparar derivados de 2-metil-3-(2-hidroxi-3-amino-propoxi)-4,5-di-oximetil-piridina

Info

Publication number
AR226356A1
AR226356A1 AR285225A AR28522581A AR226356A1 AR 226356 A1 AR226356 A1 AR 226356A1 AR 285225 A AR285225 A AR 285225A AR 28522581 A AR28522581 A AR 28522581A AR 226356 A1 AR226356 A1 AR 226356A1
Authority
AR
Argentina
Prior art keywords
oxymethyl
propoxy
hydroxy
amino
methyl
Prior art date
Application number
AR285225A
Other languages
English (en)
Spanish (es)
Original Assignee
Labaz Sanofi Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labaz Sanofi Nv filed Critical Labaz Sanofi Nv
Application granted granted Critical
Publication of AR226356A1 publication Critical patent/AR226356A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AR285225A 1980-05-19 1981-05-07 Procedimiento para preparar derivados de 2-metil-3-(2-hidroxi-3-amino-propoxi)-4,5-di-oximetil-piridina AR226356A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8016516 1980-05-19

Publications (1)

Publication Number Publication Date
AR226356A1 true AR226356A1 (es) 1982-06-30

Family

ID=10513518

Family Applications (1)

Application Number Title Priority Date Filing Date
AR285225A AR226356A1 (es) 1980-05-19 1981-05-07 Procedimiento para preparar derivados de 2-metil-3-(2-hidroxi-3-amino-propoxi)-4,5-di-oximetil-piridina

Country Status (32)

Country Link
US (1) US4374841A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0040591B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS5711966A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR226356A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE3859T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU542463B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG35327A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1152080A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (1) CS223842B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD159071A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3160480D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK217481A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG15890A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8203845A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI811525A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR82343B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU183441B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE51179B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL62602A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN151915B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS1183B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA19147A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO811680L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ196766A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA06811A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL129213B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT72992B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO81943A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SU (1) SU1077566A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU126281A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA812448B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZW (1) ZW9681A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663354A (en) * 1984-04-26 1987-05-05 Klinge Pharma Gmbh Use of etilefrin and etilefrin pivalate in the long term treatment of circulatory disorders not due to hypotonia
DE3519693A1 (de) * 1985-06-01 1987-01-02 Basf Ag Pyridin-derivate, ihre herstellung und verwendung
US6051587A (en) * 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
EP1169322B8 (en) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6
WO2001003682A2 (en) * 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
CA2383252A1 (en) 1999-08-24 2001-03-01 Medicure International Inc. Treatment of cardiovascular related pathologies
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
DE60110054T2 (de) 2000-02-29 2006-03-09 Medicure International Inc. Cardioprotektive phosphonate
AU784840B2 (en) 2000-03-28 2006-07-06 Medicure International Inc. Treatment of cerebrovascular disease
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
DE60128912T9 (de) 2000-07-07 2008-06-26 Medicure International Inc. Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
JP4048166B2 (ja) * 2002-11-18 2008-02-13 三井製糖株式会社 血糖値上昇抑制剤及び体脂肪蓄積抑制剤並びに食用材料
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
US20070167411A1 (en) * 2003-03-27 2007-07-19 Medicure International Inc. Compositions for treating angina
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
EP1817288A4 (en) * 2004-10-28 2009-08-26 Medicure Int Inc DUAL ANTIPLÄTTCHEN / ANTIKOAGULANS PYRIDOXINANALOGE
AU2006317440A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR207133A1 (es) * 1973-02-20 1976-09-15 Ciba Geigy Ag Procedimiento para la elaboracion de derivados de 1-piridiloxi 1-pirimidiniloxi y 1-piraziniloxi-2-hidroxi-3-amino-propano
US4115575A (en) * 1973-02-20 1978-09-19 Ciba-Geigy Corporation 2-(3-Amino-2-hydroxy-propoxy)-pyrazines
GB1485919A (en) * 1975-08-12 1977-09-14 Grindstedvaerket As Pyridine derivatives
DE2711655A1 (de) * 1977-03-17 1978-09-21 Basf Ag Pyridinyl-aminoalkylaether
US4210653A (en) * 1978-06-27 1980-07-01 Merck & Co., Inc. Pyridyloxypropanolamines

Also Published As

Publication number Publication date
EG15890A (en) 1987-03-30
AU7053581A (en) 1981-11-26
HU183441B (en) 1984-05-28
CS223842B2 (en) 1983-11-25
EP0040591B1 (fr) 1983-06-22
IS2631A7 (is) 1981-11-11
SU1077566A3 (ru) 1984-02-29
FI811525L (fi) 1981-11-20
GR82343B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-12-13
PT72992A (en) 1981-06-01
PT72992B (en) 1982-07-01
NZ196766A (en) 1984-02-03
RO81943A (ro) 1983-06-01
NO811680L (no) 1981-11-20
ATE3859T1 (de) 1983-07-15
BG35327A3 (bg) 1984-03-15
OA06811A (fr) 1982-12-31
RO81943B (ro) 1983-05-30
AU542463B2 (en) 1985-02-21
IL62602A (en) 1984-06-29
IE811085L (en) 1981-11-19
IL62602A0 (en) 1981-06-29
FI811525A7 (fi) 1981-11-20
YU126281A (en) 1984-02-29
MA19147A1 (fr) 1981-12-31
IE51179B1 (en) 1986-10-29
PL129213B1 (en) 1984-04-30
ES502276A0 (es) 1982-04-01
DD159071A5 (de) 1983-02-16
DK217481A (da) 1981-11-20
CA1152080A (en) 1983-08-16
IS1183B6 (is) 1985-05-13
ZA812448B (en) 1982-04-28
JPS5711966A (en) 1982-01-21
IN151915B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1983-09-03
ES8203845A1 (es) 1982-04-01
US4374841A (en) 1983-02-22
DE3160480D1 (en) 1983-07-28
ZW9681A1 (en) 1982-01-20
EP0040591A1 (fr) 1981-11-25
PL231193A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-07-05

Similar Documents

Publication Publication Date Title
ES507715A0 (es) Procedimiento para preparar derivados de 1-sulfo-2-oxoazetidina .
ES516588A0 (es) Procedimiento para preparar derivados de piridona.
AR226356A1 (es) Procedimiento para preparar derivados de 2-metil-3-(2-hidroxi-3-amino-propoxi)-4,5-di-oximetil-piridina
ES514016A0 (es) Procedimiento para preparar derivados de n-fenilpirazol.
NO813208L (no) Fremgangsmaate for fremstilling av 3-aryl-5-isotiazol-derivater.
ES505898A0 (es) Procedimiento para preparar derivados de pirimidona
ES517332A0 (es) Procedimiento para preparar derivados de feniltiadiazinona.
ES506842A0 (es) Procedimiento para preparar derivados 3-aminopropoxifenili- cos.
ES510258A0 (es) Procedimiento para preparar derivados de quanadina.
ES509044A0 (es) Procedimiento para preparar derivados de fenilsulfonilurea sustituidos.
ES517333A0 (es) Procedimientos para preparar derivados piridazinona.
MX6752E (es) Procedimiento para preparar derivados de carboestirilos
ES508280A0 (es) Procedimiento para preparar derivados de cefalosporina.
MX6975E (es) Procedimiento para preparar s,s-dialquil-fosforoditioatos de o-alquilo
ES527945A0 (es) Procedimiento para preparar derivados de bencilcarbamoilpiridina.
ES509734A0 (es) Procedimiento para preparar derivados de benzotiadiazol-amina.
ES500796A0 (es) Procedimiento para preparar derivados de pirimidona
MX157614A (es) Procedimiento para preparar derivados de isohexido
ES514478A0 (es) Procedimiento para la obtencion de derivados de diaril-imidazol.
ES525333A0 (es) Procedimiento para preparar derivados de sulfamoilbenzofenona.
ES515567A0 (es) Procedimiento para preparar derivados de fenantreno.
ES515767A0 (es) Procedimiento para preparar derivados de indano.
AR229509A1 (es) Procedimiento para preparar derivados de 2-halogeno-acetanilidas
ES502909A0 (es) Procedimiento de preparar derivados de quinoxalina-1,4-dio- xido
ES504681A0 (es) Procedimiento para preparar derivados de 11- hidroxi-13 oxa-prostaglandina.